ONCOLOGY INSTITUTE INC/THE (TOI)
US68236X1000 - Common Stock
Overall TOI gets a fundamental rating of 3 out of 10. We evaluated TOI against 114 industry peers in the Health Care Providers & Services industry. TOI may be in some trouble as it scores bad on both profitability and health. TOI is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year TOI has reported negative net income.
TOI had a negative operating cash flow in the past year.
TOI had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TOI reported negative operating cash flow in multiple years.
1.2 Ratios
TOI has a worse Return On Assets (-32.58%) than 82.46% of its industry peers.
TOI has a Return On Equity of -200.33%. This is amonst the worse of the industry: TOI underperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.58% | ||
| ROE | -200.33% | ||
| ROIC | N/A |
ROA(3y)-12.59%
ROA(5y)-13.25%
ROE(3y)-43.14%
ROE(5y)-37.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 15.33%, TOI is doing worse than 71.93% of the companies in the same industry.
TOI's Gross Margin has declined in the last couple of years.
TOI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.26%
GM growth 5Y-4.59%
2. Health
2.1 Basic Checks
TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TOI has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TOI has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.04, we must say that TOI is in the distress zone and has some risk of bankruptcy.
TOI has a Altman-Z score of 0.04. This is in the lower half of the industry: TOI underperforms 66.67% of its industry peers.
A Debt/Equity ratio of 3.08 is on the high side and indicates that TOI has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.08, TOI is doing worse than 77.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.04 |
ROIC/WACCN/A
WACC6.31%
2.3 Liquidity
TOI has a Current Ratio of 3.31. This indicates that TOI is financially healthy and has no problem in meeting its short term obligations.
TOI has a better Current ratio (3.31) than 89.47% of its industry peers.
A Quick Ratio of 2.99 indicates that TOI has no problem at all paying its short term obligations.
TOI has a better Quick ratio (2.99) than 87.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
TOI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.85%.
TOI shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.41%.
TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.43% yearly.
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.26%
Revenue 1Y (TTM)28.41%
Revenue growth 3Y20.03%
Revenue growth 5Y23.43%
Sales Q2Q%21.78%
3.2 Future
The Earnings Per Share is expected to grow by 32.88% on average over the next years. This is a very strong growth
TOI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.73% yearly.
EPS Next Y38.52%
EPS Next 2Y32.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.38%
Revenue Next 2Y22.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
TOI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TOI's earnings are expected to grow with 32.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.88%
EPS Next 3YN/A
5. Dividend
5.1 Amount
TOI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCOLOGY INSTITUTE INC/THE
NASDAQ:TOI (11/15/2024, 9:59:09 AM)
0.2151
-0.02 (-8.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.58% | ||
| ROE | -200.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.33% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.31 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)28.41%
Revenue growth 3Y20.03%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y